{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:26:15Z","timestamp":1769635575695,"version":"3.49.0"},"reference-count":18,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":84,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,9,27]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Data on the proton pump inhibitor lansoprazole in paediatric patients are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To investigate the pharmacokinetics, optimal dosage and efficacy of lansoprazole in paediatric patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A 24\u2010h gastric pH recording and a pharmacokinetic study were performed after 7\u2003days of lansoprazole, 17\u2003mg\/m<jats:sup>2<\/jats:sup>, in 23 patients with reflux oesophagitis (median age, 3.5\u2003years). Response was defined as pH\u2003&gt;\u20033 for &gt;\u200365% of the recording. The dosage was doubled in non\u2010responders. Patients with no response on day 14 were excluded. Responders underwent endoscopy after 4\u2003weeks on the response\u2010inducing dosage; abnormal findings led to a repeat endoscopy after four additional weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Nine patients responded to 17\u2003mg\/m<jats:sup>2<\/jats:sup> and six to 30.3\u2003mg\/m<jats:sup>2<\/jats:sup>. On day 7, time with pH\u2003&gt;\u20033 was significantly correlated with the area under the plasma concentration\u2013time curve (<jats:italic>P<\/jats:italic>=0.003). The area under the plasma concentration\u2013time curve was significantly greater in the nine responders to 17\u2003mg\/m<jats:sup>2<\/jats:sup> than in the 14 other patients. Pharmacokinetic parameters were similar in responders and non\u2010responders to the higher dose. After 4\u2003weeks, oesophagitis was healed in 80% of responders. Adverse events occurred in three patients and required treatment discontinuation in one.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>Lansoprazole is effective and safe in children. The optimal starting dosage is 30\u2003mg\/m<jats:sup>2<\/jats:sup> or 1.4\u2003mg\/kg.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.01076.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:45:08Z","timestamp":1047354308000},"page":"1397-1402","source":"Crossref","is-referenced-by-count":49,"title":["Lansoprazole in children: pharmacokinetics and efficacy in reflux oesophagitis"],"prefix":"10.1111","volume":"15","author":[{"given":"C.","family":"Faure","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Khan Shaghaghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Popon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Laurence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F.","family":"Mougenot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Hankard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Jacqz\u2010Aigrain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_7_2_2","first-page":"799","article-title":"Possible mechanism for the inhibition of gastric (H+, K+)\u2010adenosine triphosphatase by the proton pump inhibitor AG\u20101749","volume":"248","author":"Nagaya H","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199754030-00010"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199703000-00003"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00293.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(79)80361-3"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4347(95)00068-T"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002280050111"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199244020-00007"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.3.490"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104043241406"},{"key":"e_1_2_7_12_2","first-page":"S97","article-title":"Pharmacokinetics of lansoprazole in adolescents with GERD","volume":"31","author":"Gunasekaran T","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_7_13_2","first-page":"S97","article-title":"Adolescent patients with gastroesophageal reflux disease: results from a randomized trial of lansoprazole","volume":"31","author":"Gupta SK","year":"2000","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200007001-00004"},{"key":"e_1_2_7_15_2","first-page":"805","article-title":"Identification of the human P450 enzymes involved in lanzoprazole metabolism","volume":"277","author":"Pearce RE","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0031-3955(05)70463-6"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03256.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1067\/mpd.2000.109607"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-200003000-00007"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01076.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.01076.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.01076.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T15:26:21Z","timestamp":1695828381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.01076.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9,27]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2001,9,27]]}},"alternative-id":["10.1046\/j.1365-2036.2001.01076.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.01076.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,9,27]]}}}